Enhancement of 5-aminolaevulinic acid-induced photodynamic therapy in normal rat colon using hydroxypyridinone iron-chelating agents
1998

Enhancing Cancer Treatment with Iron Chelators

Sample size: 8 publication Evidence: moderate

Author Information

Author(s): A Curnowl, BW Mcilroy, MJ Postle-Hacon, JB Porter, AJ MacRobert, SG Bown

Primary Institution: National Medical Laser Centre, Institute of Surgical Studies, University College London Medical School

Hypothesis

Can hydroxypyridinone iron-chelating agents enhance the effectiveness of 5-aminolaevulinic acid-induced photodynamic therapy without increasing the ALA dose?

Conclusion

The simultaneous administration of the iron chelator CP94 with ALA significantly increases the area of necrosis produced by photodynamic therapy.

Supporting Evidence

  • CP94 doubled the PPIX fluorescence in the colonic mucosa compared to ALA alone.
  • The area of necrosis was three times larger with CP94 and ALA than with ALA alone.
  • Fluorescence microscopy confirmed that PPIX was the predominant porphyrin present.

Takeaway

This study shows that adding a special iron medicine can make cancer treatment work better without needing to give more of the main medicine.

Methodology

Normal Wistar rats were treated with ALA and iron chelators, and fluorescence microscopy was used to measure the effects on tissue.

Limitations

The study was conducted on rats, and results may not directly translate to humans.

Participant Demographics

Normal, female, Wistar rats (120-200 g)

Statistical Information

P-Value

<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication